The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Validation of the IWG 2023 criteria for clinical benefit in HR-MDS
Maximilian Stahl, MD, Yale Cancer Center, New Haven, CT, discusses the
validation of the International Working Group (IWG) 2023 criteria for clinical benefit in higher-risk myelodysplastic syndromes (HR-MDS). Dr Stahl highlights that the new criteria have been validated using both retrospective and prospective clinical data sets, demonstrating their association with clinical benefit. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we have been using the old working group criteria. This is the 2006 working group criteria for many years. And in 2023, a group at Yale with many collaborators around the world came up with new working group criteria that hopefully capture clinical benefit better. And we have had now multiple papers that validated those working group criteria in a retrospective fashion but this was the first time that we actually used a clinical trial, so a prospective clinical data set to validate those working group criteria and importantly we found that composite complete response (CR) as defined by the new 2023 working group criteria was clearly associated with clinical benefit...
So we have been using the old working group criteria. This is the 2006 working group criteria for many years. And in 2023, a group at Yale with many collaborators around the world came up with new working group criteria that hopefully capture clinical benefit better. And we have had now multiple papers that validated those working group criteria in a retrospective fashion but this was the first time that we actually used a clinical trial, so a prospective clinical data set to validate those working group criteria and importantly we found that composite complete response (CR) as defined by the new 2023 working group criteria was clearly associated with clinical benefit. And we’re now about to write up a publication based on both this prospective data set as well as a very large retrospective data set, the validation data set, to show the benefit of those working group criteria and that they should really represent the standard of assessing response in MDS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
